We were delighted to discuss with Kim Papp (Probity Medical Research, Waterloo, ON, Canada) the results of the phase IIb study assessing the efficacy, safety and tolerability of sonelokinab (M1095), and IL-17 A/F nanobody, in patients with moderate-to-severe chronic plaques psoriasis (Clinical Trial Identifier: NCT03384745)
- What are the major unmet needs in the treatment of chronic plaque-type psoriasis? (0:22)
- Could you tell us a little about sonelokinab and its mechanism of action? (1:29)
- What were the aims, design and inclusion criteria of the Phase IIb study? (2:58)
- What have we learned from the efficacy and safety findings of the study? (5:13)
- What will be the next steps in the clinical development of sonelokinab in this indication? (7:54)
Disclosures: Kim Papp as acted as an advisor/speaker/consultant/steering committee member/researcher for AbbVie, Akros, Allergan, Amgen, Anacor, Arcutis, Astellas, AstraZeneca, Bausch Health (Valeant), Baxalta, Baxter, Boehringer Ingelheim, Bristol-Myers Squibb, Can-Fite, Celgene, Coherus, Dermira, Dow, Forward Pharma, Galderma, Genentech, Gilead, GlaxoSmithKline, InflaRx, Janssen, Kyowa Kirin, LEO Pharma, Lilly, MedImmune, Meiji Seika Pharma, Merck, Mitsubishi Tanabe Pharma, Moberg Pharma, Novartis, Pfizer, Regeneron, Roche, Sanofi Genzyme, Takeda, and UCB.
Support: Interview and filming supported by Touch Medical Media.
Filmed as highlights of the 29th EADV Virtual Congress 2020.
Share this Video
Related Videos In Psoriasis
Diamant Thaçi, EADV 2020: Long-term Efficacy of Tildrakizumab in Psoriasis
It was an honour to talk with Prof. Diamant Thaçi (University of Lübeck, Lübeck, Germany) about the reSURFACE clinical studies and in particular, long-term data from reSURFACE 2 (NCT01729754). Results from the study, which investigated the anti-IL-23p19 monoclonal antibody, tildrakizumab in the treatment of patients with moderate-to-severe plaque psoriasis, were presented in the abstract entitled […]
Lluís Puig, EADV 2020 – New Therapeutic Targets in Psoriasis
We were delighted to be able to speak with Lluís Puig (Universitat Autònoma de Barcelona School of Medicine, Barcelona, Spain) about novel pathophysiology-based therapeutic agents in the treatment of psoriasis. His full presentation entitled ‘New therapeutic targets based on pathophysiology’ was presented at the EADV Virtual Congress 2020. Questions Could you give us a brief […]
Kim Papp, EADV 2020 – Sonelokinab for Chronic Plaque Psoriasis
We were delighted to discuss with Kim Papp (Probity Medical Research, Waterloo, ON, Canada) the results of the phase IIb study assessing the efficacy, safety and tolerability of sonelokinab (M1095), and IL-17 A/F nanobody, in patients with moderate-to-severe chronic plaques psoriasis (Clinical Trial Identifier: NCT03384745) Questions What are the major unmet needs in the treatment […]
Journal articles and more to your inbox
Get the latest clinical insights from touchIMMUNOLOGYSign me up!